Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Emily Wagner

Physician Assistant Baton Rouge, LA Physician Assistant

NPI 1568864015 CMS profile 10460778

10101 Park Rowe Ave, Ste 200, Baton Rouge, LA 70810

Open in the dashboard

General payments

$8,217

304 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Emily Wagner of Baton Rouge, LA is reported in the CMS Open Payments database as having received $8,217 across 304 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,908 56
2024 General $1,422 61
2023 General $959 47
2022 General $1,524 74
2021 General $1,404 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emily Wagner
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Emily Wagner were reported at $2,908. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Emily Wagner Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,404 $132 $37–$438 $132
2022 $1,524 $155 $48–$522 $149
2023 $959 $167 $52–$557 $160
2024 $1,422 $178 $55–$600 $164
2025 $2,908 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $2,740 44 payments
  2. Abbott Laboratories $1,940 107 payments
  3. Nevro Corp. $898 33 payments
  4. Collegium Pharmaceutical, Inc. $432 23 payments
  5. Globus Medical, Inc. $378 13 payments
  6. Merz Pharmaceuticals, LLC $289 11 payments
  7. AbbVie, Inc. $285 5 payments
  8. Ipsen Biopharmaceuticals, Inc $180 8 payments
  9. Horizon Therapeutics plc $173 11 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $129 8 payments
  11. Other $773 41 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,751 294 payments
  2. Travel and Lodging $1,466 10 payments
Products named General payments · program years 2021–2025
  1. SYNCHROMEDII $2,249 29 payments
  2. Proclaim IPG $494 15 payments
  3. Senza Spinal Cord Stimulator $481 17 payments
  4. Omnia $414 16 payments
  5. Senza Spinal Cord Stimulator $365 12 payments
  6. PROCLAIM Neuromodulation $331 20 payments
  7. PROCLAIM Neuromodulation $297 18 payments
  8. INTELLIS ADAPTIVESTIM $291 7 payments
  9. BELBUCA $289 14 payments
  10. VRAYLAR $254 3 payments
  11. Other $3,068 173 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$22,609

Of which drugs: $1,578

Medicare patients

212

Average age 71

Services billed

953

131 women, 81 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 34%
Depression 33%
Ischemic heart disease 27%
Chronic kidney disease 23%
Cancer 16%
Heart failure 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ketorolac tromethamine, per 15 mg J1885 Office 19 82 $39

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BELBUCA
  • Collegium Pharmaceutical, Inc. $159
$159 — —
DYSPORT
  • Ipsen Biopharmaceuticals, Inc $84
$84 — —
Xeomin
  • Merz Pharmaceuticals, LLC $69
$69 — —
LEVORPHANOL TARTRATE
  • Virtus Pharmaceuticals LLC $43
$43 — —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $33
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

304 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record